Abstract
The activity of meropenem against 106 imipenem-resistant (MIC ≥ 8 mg/l) clinical isolates, and the frequency of resistance to meropenem and imipenem among 24Enterobacteriaceae was determined. Both agents selected colonies on agar but 20–80 % were susceptible after one subculture and 72 % of the mutants reverted to susceptibility 1 to 6 months after selection. All isolates and stable mutants were inhibited by > 1 mg/l meropenem, although the MIC of imipenem was 4–16 mg/l. Three of sixXanthomonas maltophilia isolates were susceptible to meropenem (MICs 2–4 mg/l).Pseudomonas aeruginosa lacking outer membrane protein D2 were resistant to meropenem, although isolates with substantially reduced expression of this protein were susceptible. None of the imipenem-resistant gram-positive bacteria were susceptible to meropenem. There was no clear correlation between altered outer membrane protein expression and decreased susceptibility to carbapenems, and there was no apparent involvement of plasmid or chromosomal β-lactamase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindley AJ, Nairn K: In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrobial Agents and Chemotherapy 1989, 33: 215–222.
Sumita Y, Inoue M, Mitsuhashi S: In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. New Antimicrobial Agents 1989, 8: 908–916.
Jones RN, Aldridge KE, Allen SD, Barry AL, Fuchs PC, Gerlack EH, Pfaller MA: Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrobial Agents and Chemotherapy 1989, 33: 562–565.
King A, Boothman C, Phillips I: Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 31–46.
Bauernfeind A, Jungwirth R, Schweihart S: In vitro activity of meropenem, imipenem, and penem HRE 664 and ceftazidime against clinical isolates from West Germany. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 73–84.
Kitzis MD, Acar JF, Gutmann L: Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect against staphylococci. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 125–132.
Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R: Comparative in-vitro activity of meropenem against clinical isolates includingEnterobacteriaceae with expanded spectrum β-lactamases. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 133–142.
Sanders CC, Sanders WE, Thomson KS, Iaconis JP: Meropenem: activity against resistant gram-negative bacteria and interactions with β-lactamases. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 187–196.
Yang Y, Livermore DM: Interactions of meropenem with class I chromosomal β-lactamases. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 207–218.
Trias J, Nikaido H: Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane ofPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1990, 34: 52–57.
Watanabe M, Iyobe S, Inoue M, Mitsuhashi S: Transferrable imipenem resistance inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1991, 35: 147–151.
Livermore DM, Yang Y: Comparative activity of meropenem againstPseudomonas aeruginosa strains with well-characterised resistance mechanisms. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 149–160.
Margaret BS, Drusano GL, Standiford HC: Emergence of resistance to carbapenem antibiotics inPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 161–168.
Yang Y, Wu P, Livermore DM: Biochemical characterisation of a β-lactamase that hydrolyses penems and carbapenems from twoSerratia marcescens isolates. Antimicrobial Agents and Chemotherapy 1990, 34: 755–758.
Piddock LJV, Traynor EA, Wise R: A comparison of the mechanism of decreased susceptibility of aztreonam-resistant and ceftazidime-resistantEnterobacteriaceae. Journal of Antimicrobial Chemotherapy 1990, 26: 749–762.
Sanders CC, Sanders WE: Emergence of resistance to cefamandole: possible role of cefoxitin-inducible β-lactamase. Antimicrobial Agents and Chemotherapy 1979, 15: 792–797.
Michea-Hamzepour M, Furet XY, Pechere JC: Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane ofPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1991, 35: 2209–2217.
Piddock LJV, Hall MC, Walters RN: Phenotypic characterisation of quinolone-resistant mutants ofEnterobacteriaceae selected from wild-type gyrA and multiply resistant (marA) type strains. Antimicrobial Agents and Chemotherapy 1991, 28: 185–198.
Stoorvogel J, van Bussel MJ, Tommassen J, van de Klundert JAM: Molecular characterisation of anEnterobacter cloacae outer membrane protein (OmpX). Journal of Bacteriology 1991, 173: 156–160.
Lee EH, Nicolas MH, Kitzis MD, Pialoux G, Collatz E, Gutmann L: Association of two resistance mechanisms in a clinical isolate ofEnterobacter cloacae with high-level resistance to imipenem. Antimicrobial Agents and Chemotherapy 1991, 35: 1093–1098.
Raimondi A, Traverso A, Nikaido H: Imipenem- and meropenem-resistant mutants ofEnterobacter cloacae andProteus rettgeri lack porins. Antimicrobial Agents and Chemotherapy 1991, 35: 1174–1180.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Piddock, L.J.V., Turner, H.L. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistantEnterobacteriaceae . Eur. J. Clin. Microbiol. Infect. Dis. 11, 1186–1191 (1992). https://doi.org/10.1007/BF01961143
Issue Date:
DOI: https://doi.org/10.1007/BF01961143